Lenalid 15 Capsule contains Lenalidomide 15 mg, an immunomodulatory agent primarily indicated for the treatment of multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma. Lenalidomide exerts antineoplastic effects by modulating the immune system, inhibiting angiogenesis, and inducing apoptosis in malignant cells. It is typically prescribed as part of combination therapy or as monotherapy depending on the clinical scenario. The capsule should be administered orally, with dosing individualized based on patient response, renal function, and hematologic parameters. Common adverse effects include neutropenia, thrombocytopenia, anemia, fatigue, and gastrointestinal disturbances. Due to its teratogenic potential, strict pregnancy prevention measures must be implemented during treatment and for a specified period after discontinuation. Regular monitoring of blood counts, renal function, and potential thromboembolic events is essential to optimize safety and efficacy. Lenalid 15 Capsule should be used under specialist supervision with adherence to recommended guidelines to ensure appropriate patient selection and management. It is contraindicated in patients with hypersensitivity to Lenalidomide or any capsule components. Patients should be advised to report any signs of infection, bleeding, or unusual symptoms promptly. This medication is a critical component in the management of certain hematologic malignancies, offering improved clinical outcomes when used appropriately.